Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 CAR-T cells for relapsed or refractory malignant B-cell neoplasms
RBR-7cr9yvfPhase 2Not yet recruiting
- Sponsor
- Hospital Israelita Albert Einstein
- Start
- Sep 2022
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous anti-CD19 CAR-T cells in acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and non-Hodgkin lymphoma (NHL), sponsored by Hospital Israelita Albert Einstein. Primary endpoint: Safety and toxicity. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
autologous anti-CD19 CAR-T cells
03
Conditions
acute lymphoblastic leukemia (ALL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on RBR-7cr9yvf.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-7cr9yvf.